Department of Neurosurgery, Xiangya Hospital of Central South University, Changsha 410008, Hunan, China.
Department of Microbiology, Xiangya School of Medicine, Central South University, Changsha 410008, Hunan, China.
Biomed Pharmacother. 2020 Jul;127:110193. doi: 10.1016/j.biopha.2020.110193. Epub 2020 May 11.
High-grade gliomas (HGG) are the most common malignant intracranial tumors with poor prognosis. Current treatments have not yielded optimal remission rates; there are no standard treatments for recurrent and drug-resistant gliomas. Tumor treating fields, which was recently approved by the Food and Drug Administration (FDA), could significantly improve progression free survival and the overall survival of glioma patients. In this review, we elaborate on the mechanism of tumor treating fields in tumor cells and detail various preclinical and clinical studies on gliomas. Tumor treating fields could be a promising option for patients with malignant tumors for which there are no standard treatment plans. Moreover, we identify several potential problems for the practical application of tumor treating fields and predict future directions for further studies. Tumor treating fields may be a potential therapy with high efficacy, fewer adverse effects, and high cost-effectiveness.
高级别胶质瘤（HGG）是最常见的颅内恶性肿瘤，预后较差。目前的治疗方法并未产生最佳的缓解率；对于复发性和耐药性胶质瘤，尚无标准治疗方法。肿瘤电场治疗（Tumor Treating Fields，TTFields）最近获得美国食品和药物管理局（FDA）批准，可显著改善胶质瘤患者的无进展生存期和总生存期。在这篇综述中，我们详细阐述了肿瘤电场治疗在肿瘤细胞中的作用机制，并详细介绍了针对胶质瘤的各种临床前和临床研究。肿瘤电场治疗可能是一种有前途的治疗选择，适用于尚无标准治疗方案的恶性肿瘤患者。此外，我们还确定了肿瘤电场治疗实际应用中存在的几个潜在问题，并预测了未来进一步研究的方向。肿瘤电场治疗可能是一种具有高效、低副作用和高成本效益的潜在治疗方法。
